New Y-trap Technology Shows Promise as Cancer Immunotherapy – Immuno-Oncology News
Immuno-Oncology News |
New Y-trap Technology Shows Promise as Cancer Immunotherapy
Immuno-Oncology News … the checkpoint inhibitors Tecentriq (atezolizumab) or Bavencio (avelumab) that also target PD-L1. This Y-trap slowed the growth of tumors that had not responded to these medications. “These first-in-class Y-traps are just the beginning. We have … |
